SCHEMBL3143891

SCHEMBL3143891

CN(C)CCOc1ccc(S(=O)(=O)O)cc1.[NaH]

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.53
LTA4H P09960 2/20 0.51
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
LSS P48449 1/20 0.48
KDM4E B2RXH2 4/20 0.48
POLB P06746 1/20 0.48
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
STS P08842 1/20 0.45
CHRNB2 P17787 1/20 0.45
CHRNA4 P43681 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5971888 0.98 HRH3 (0.54) HRH3LTA4HKEAP1NFE2L2LSS
Hydrochloric Acid SCHEMBL4774350 0.89 KDM4E (0.57) HRH3LSSKDM4EALDH1A1SMN1; SMN2
SCHEMBL12743793 0.82 CA12 (0.50) HRH3ALDH1A1SMN1; SMN2
SCHEMBL6095279 0.81 CA12 (0.67) HRH3LTA4HKEAP1NFE2L2
SCHEMBL3143886 0.81 HRH3 (0.54) HRH3LTA4HKEAP1NFE2L2LSS
SCHEMBL7008138 0.81 HRH3 (0.54) HRH3LTA4HKEAP1NFE2L2LSS
SCHEMBL7368029 0.81 CA12 (0.66) LTA4HSMN1; SMN2
SCHEMBL19874502 0.80 CA12 (0.50) HRH3KDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL19874539 0.80 CA12 (0.50) HRH3KDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL18624978 0.80 CA12 (0.53) HRH3ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687546-B2 Quaternary ammonium compound, process for producing the same, therapeutic agent for cerebrovascular disorder, and therapeutic agent for heart disease ACTIVUS PHARMA CO., LTD. (JP) 2010-03-30 US disclosed
US-20080269345-A1 Quarternary Ammonium Compound, Process for Producing the Same, Therapeutic Agent for Cerebrovascular Disorder, and Therapeutic Agent for Heart Disease DAINIPPON INK AND CHEMICALS, INC. (JP) 2008-10-30 US disclosed
EP-1736464-A1 QUATERNARY AMMONIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, THERAPEUTIC AGENT FOR CEREBROVASCULAR DISORDER, AND THERAPEUTIC AGENT FOR HEART DISEASE Dainippon Ink and Chemicals, Incorporated (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269345-A1 Quarternary Ammonium Compound, Process for Producing the Same, Therapeutic Agent for Cerebrovascular Disorder, and Therapeutic Agent for Heart Disease HRH4, KCNH3, ARGLU1 HRH3 9/4885LTA4H 2678/4885KEAP1 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.